Cardiff Oncology Corp (CRDF): יחס מחיר להכנסות

Cardiff Oncology, Inc. (CRDF) focuses on developing targeted therapies based on a rigorous scientific approach and clinician expertise. The historical P/S trend on this GURU.Markets chart, where 99.80 captures the current indicator value, highlights the pressure from pharma behemoths in the battle for patents. High R&D expenditures define the financial profile, keeping margins at a preparatory level.

The P/S ratio determines the market value of a single ruble of revenue, allowing investors to distinguish between objective capitalization and speculative market expectations. By analyzing the price-to-sales multiple, one can assess the valuation volatility of Cardiff Oncology, Inc. (CRDF), where a high price-to-sales ratio reflects confidence in the success of innovative PLK1 inhibitors amid fierce biotech competition and dependence on clinical trial results.